Merck & Co. Inc.'s Keytruda (pembrolizumab) finally reached the blockbuster benchmark in 2016 and while it still tails Bristol-Myers Squibb Co.’s PD-1 inhibitor Opdivo, there are signs Merck’s anti-PD-1 cancer immunotherapy is positioned to dominate in the key first-line non-small cell lung cancer setting thanks to first-mover advantage and what one analyst called smart development and filing strategies.
The pharma reported flat overall revenues for fourth quarter 2016 on Feb. 2, but called Keytruda a key growth product...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?